BR112021016812A2 - Compostos para tratar e prevenir complicações associadas a net - Google Patents
Compostos para tratar e prevenir complicações associadas a netInfo
- Publication number
- BR112021016812A2 BR112021016812A2 BR112021016812A BR112021016812A BR112021016812A2 BR 112021016812 A2 BR112021016812 A2 BR 112021016812A2 BR 112021016812 A BR112021016812 A BR 112021016812A BR 112021016812 A BR112021016812 A BR 112021016812A BR 112021016812 A2 BR112021016812 A2 BR 112021016812A2
- Authority
- BR
- Brazil
- Prior art keywords
- net
- compounds
- methods
- relates
- chemical stability
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
compostos para tratar e prevenir complicações associadas a net. a presente invenção refere-se a compostos com alta estabilidade química e métodos para inibir a atividade patológica de nets em um indivíduo. em particular, a invenção refere-se a compostos com alta estabilidade química, usos dos mesmos e métodos para inibir ou melhorar enfermidades mediadas por net (tais como, por exemplo, sepse, síndrome da resposta inflamatória sistêmica (sirs) e lesão por reperfusão e isquemia (iri)). mais particularmente, a invenção refere-se a métodos e usos de um celobiosídeo sulfatado polianiônico modificado com um pequeno substituinte glicosidicamente ligado não carregado no seu terminal redutor, em que a presença do substituinte resulta em uma molécula com alta estabilidade química sem afetar a capacidade da molécula de ser eficaz na terapia de enfermidades mediadas por net. por exemplo, a presente invenção refere-se a métodos e usos de sulfato de b-o-metilcelobiosídeo (mcbs) ou um sal farmaceuticamente aceitável do mesmo (por exemplo, mcbs.na), na terapia de uma variedade de enfermidades mediadas por net em indivíduos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/AU2019/050156 WO2020172698A1 (en) | 2019-02-25 | 2019-02-25 | Compounds for treating and preventing net associated complications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021016812A2 true BR112021016812A2 (pt) | 2021-11-16 |
Family
ID=72238229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021016812A BR112021016812A2 (pt) | 2019-02-25 | 2019-02-25 | Compostos para tratar e prevenir complicações associadas a net |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220168327A1 (pt) |
| EP (1) | EP3930726A4 (pt) |
| JP (1) | JP2022530732A (pt) |
| KR (1) | KR20210132032A (pt) |
| CN (1) | CN113473992A (pt) |
| AU (1) | AU2019431212A1 (pt) |
| BR (1) | BR112021016812A2 (pt) |
| CA (1) | CA3130405A1 (pt) |
| EA (1) | EA202192345A1 (pt) |
| IL (1) | IL285828A (pt) |
| SG (1) | SG11202109032SA (pt) |
| WO (1) | WO2020172698A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022116981A1 (zh) * | 2020-12-01 | 2022-06-09 | 远大医药（中国）有限公司 | 一种聚阴离子纤维二糖苷类化合物的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1060750B1 (en) * | 1993-03-29 | 2005-12-07 | Queen's University At Kingston | Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis |
| CA2159649A1 (en) * | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Anticoagulant compounds |
| JPH09183789A (ja) * | 1995-10-31 | 1997-07-15 | Sanwa Kagaku Kenkyusho Co Ltd | 新規な硫酸化及び燐酸化糖誘導体、その製法及び用途 |
| MXPA06007194A (es) * | 2003-12-23 | 2007-01-19 | Progen Ind Ltd | Imitaciones de glicosaminoglican (gag). |
| JP5139797B2 (ja) * | 2004-03-04 | 2013-02-06 | プロジェン ファーマシューティカルズ リミテッド | 硫酸化オリゴ糖誘導体 |
| KR101956335B1 (ko) * | 2010-12-01 | 2019-03-08 | 디 오스트레일리언 내셔널 유니버시티 | 히스톤 억제 |
| US11628179B2 (en) * | 2017-12-15 | 2023-04-18 | The Australian National University | Compounds for treating and preventing extracellular histone mediated pathologies |
| WO2022116981A1 (zh) * | 2020-12-01 | 2022-06-09 | 远大医药（中国）有限公司 | 一种聚阴离子纤维二糖苷类化合物的应用 |
-
2019
- 2019-02-25 JP JP2021549884A patent/JP2022530732A/ja active Pending
- 2019-02-25 EP EP19916556.4A patent/EP3930726A4/en active Pending
- 2019-02-25 AU AU2019431212A patent/AU2019431212A1/en active Pending
- 2019-02-25 US US17/430,756 patent/US20220168327A1/en active Pending
- 2019-02-25 BR BR112021016812A patent/BR112021016812A2/pt unknown
- 2019-02-25 KR KR1020217025633A patent/KR20210132032A/ko unknown
- 2019-02-25 EA EA202192345A patent/EA202192345A1/ru unknown
- 2019-02-25 CN CN201980092942.8A patent/CN113473992A/zh active Pending
- 2019-02-25 CA CA3130405A patent/CA3130405A1/en active Pending
- 2019-02-25 SG SG11202109032SA patent/SG11202109032SA/en unknown
- 2019-02-25 WO PCT/AU2019/050156 patent/WO2020172698A1/en unknown
-
2021
- 2021-08-24 IL IL285828A patent/IL285828A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3930726A1 (en) | 2022-01-05 |
| CA3130405A1 (en) | 2020-09-03 |
| CN113473992A (zh) | 2021-10-01 |
| SG11202109032SA (en) | 2021-09-29 |
| EA202192345A1 (ru) | 2021-12-06 |
| JP2022530732A (ja) | 2022-07-01 |
| AU2019431212A1 (en) | 2021-09-16 |
| IL285828A (en) | 2021-10-31 |
| KR20210132032A (ko) | 2021-11-03 |
| EP3930726A4 (en) | 2022-10-05 |
| US20220168327A1 (en) | 2022-06-02 |
| WO2020172698A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis | |
| Helmerhorst et al. | Bench-to-bedside review: the effects of hyperoxia during critical illness | |
| Li et al. | Carbenoxolone blocks endotoxin-induced protein kinase R (PKR) activation and high mobility group box 1 (HMGB1) release | |
| Kapoor et al. | PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice | |
| Kenworthy et al. | Social defeat induces changes in histone acetylation and expression of histone modifying enzymes in the ventral hippocampus, prefrontal cortex, and dorsal raphe nucleus | |
| Kumar et al. | Effect of zinc and paraquat co-exposure on neurodegeneration: modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats | |
| Tang et al. | Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1α and PERK signaling activation | |
| Jo et al. | Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis | |
| BR112015024678A2 (pt) | inibidor da cinase | |
| Assaife-Lopes et al. | Regulation of TrkB receptor translocation to lipid rafts by adenosine A 2A receptors and its functional implications for BDNF-induced regulation of synaptic plasticity | |
| Qiang et al. | Epigenetic mechanisms are involved in the regulation of ethanol consumption in mice | |
| Salama et al. | Toll-like receptor 4 blocker as potential therapy for acetaminophen-induced organ failure in mice | |
| Chtourou et al. | Naringenin mitigates iron-induced anxiety-like behavioral impairment, mitochondrial dysfunctions, ectonucleotidases and acetylcholinesterase alteration activities in rat hippocampus | |
| BRPI0612424A2 (pt) | composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas | |
| BR112012010333A2 (pt) | peptídeos terapêuticos | |
| Yu et al. | Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-ΚB pathway | |
| Liu et al. | Synergistic protective effect of paeoniflorin and β-ecdysterone against rotenone-induced neurotoxicity in PC12 cells | |
| BR112021016812A2 (pt) | Compostos para tratar e prevenir complicações associadas a net | |
| BRPI0410222A (pt) | tratamento de distúrbios bipolares e sintomas associados | |
| Wasyluk et al. | PARP inhibitors: An innovative approach to the treatment of inflammation and metabolic disorders in sepsis | |
| Iadecola et al. | Neurovascular protection by ischaemic tolerance: role of nitric oxide | |
| Zhang et al. | Cardiomyocyte death in sepsis: mechanisms and regulation | |
| Orio et al. | Lipopolysaccharide induces early tolerance to excitotoxicity via nitric oxide and cGMP | |
| MC Smith et al. | Hypoxia attenuates purinergic P2X receptor-induced inflammatory gene expression in brainstem microglia | |
| Villarruel et al. | Lidocaine‐induced apoptosis of gingival fibroblasts: participation of cAMP and PKC activity |